Molecular Partners AG Sponsored ADR

MOLN

Healthcare Biotechnology

Molecular Partners AG Sponsored ADR’s revenue for fiscal 2024 (year ended December 2024) was $5.6 million, down 28.0% from fiscal 2023.

Revenue
−98.9%
EPS
+8.27%
Free cash flow
+11.1%

Quarter to September 2026, against a year earlier

3.22 0.03 −0.92%
Market cap
$119.2M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
2/9
ROIC
0.00%
Net debt / EBITDA
1.7×
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
ROE

+8 more TTM periods

(57.72%) (63.08%) (63.89%) (71.08%)
ROA
(49.07%) (53.96%) (52.73%) (58.83%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(67.69%) (72.08%) (77.93%) (95.19%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(1.68) (1.63) (1.48) (1.45)
Free Cash Flow
(62.73) (61.04) (57.35) (55.74)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026